Important Notice regarding Dextenza and Klarity-C

During the September 27, 2019 Board of Optometry meeting, the Board approved Dextenza (dexamethasone ophthalmic insert) 0.4 mg and approved Klarity-C (cyclosporine) 0.1% for addition to Rule 64B13-18.002, Florida Administrative Code – Formulary of Topical Pharmaceutical Agents.

Important Note: At this time, Dextenza and Klarity-C cannot be prescribed by Certified Optometrists in Florida until the rule has been approved. Once the rule has gone through the approval process, notice will be provided on the board website and both may be prescribed by Certified Optometrists at that time.

An official website of the State of Florida How You Know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Latest News

Important Notice regarding Dextenza and Klarity-C

During the September 27, 2019 Board of Optometry meeting, the Board approved Dextenza (dexamethasone ophthalmic insert) 0.4 mg and approved Klarity-C (cyclosporine) 0.1% for addition to Rule 64B13-18.002, Florida Administrative Code – Formulary of Topical Pharmaceutical Agents.

Important Note: At this time, Dextenza and Klarity-C cannot be prescribed by Certified Optometrists in Florida until the rule has been approved. Once the rule has gone through the approval process, notice will be provided on the board website and both may be prescribed by Certified Optometrists at that time.